66 results
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
, including multi-specific CAR-Ts, and fusion proteins. Our proprietary methodologies have the potential to increase binder diversity, affinity and specificity … the Phase 3 DIVERSITY study in Crohn’s disease, a Marketing Authorization Application (MAA) was not submitted in Europe in this indication and the MAA
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
remuneration approach helps attract and retain Board members with the appropriate caliber, taking into account expertise, geography, gender and diversity
6-K
EX-99.1
GLPG
Galapagos NV
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
the Phase 3 DIVERSITY study in Crohn’s disease, a Marketing Authorization Application (MAA) was not submitted in Europe in this indication and the MAA … to €190.2 million, compared to €245.3 million in 2022. This decrease was mainly due to the discontinuation of the DIVERSITY clinical trials in CD
6-K
EX-99.1
GLPG
Galapagos NV
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
development. This was a consequence of the topline results from the Phase 3 DIVERSITY trial with filgotinib in CD and our decision not to submit a Marketing
6-K
EX-99.1
9bg z2uw7pv
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.2
4j8sw l9ynb3amxx582z
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
r3pe3xcfj1vilhnvog
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
2kginhfsqc5y4miz
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.2
0nxu7i1y8 bmkd6qt42r
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am
6-K
EX-99.1
w53 hv027objo7zr1ri6
4 Nov 22
Galapagos presents roadmap for pipeline and commercial growth at its R&D Day 2022
4:57pm
6-K
EX-99.1
17w c42q6
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.2
3nes8ozislb2odek
8 Aug 22
First key steps in pipeline rebuild and strong commercial progress in H1 2022
4:59pm
6-K
EX-99.1
ynvnd0ic0kkgix
23 Jun 22
Galapagos to acquire CellPoint and AboundBio to accelerate access to next-generation cell therapies
11:21am
6-K
EX-99.2
ixizwqow 7zepj2
6 May 22
Current report (foreign)
5:18pm
6-K
EX-99.3
9qishwx70dbe n4e
11 Apr 22
Current report (foreign)
5:14pm
6-K
EX-99.1
itn1c
24 Feb 22
Galapagos 2021 results set stage for future growth
5:19pm
6-K
EX-99.1
kd3g4w6m woyc
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm
6-K
EX-99.2
7on368hih8mc1p ahpt
8 Nov 21
Galapagos reports commercial and operational progress at Q3 financial results
4:03pm